ebselen has been researched along with 2019 Novel Coronavirus Disease in 20 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ebselen is an organoselenium compound exhibiting hydroperoxide- and peroxynitrite-reducing activity, acting as a glutathione peroxidase and peroxiredoxin enzyme mimetic." | 2.66 | Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections. ( Parnham, MJ; Sies, H, 2020) |
| "Ebselen (SPI-1005) is an active selenoorganic compound that can be found potential inhibitory activity against different types of viral infections such as zika virus, influenza A virus, HCV, and HIV-1; and also be found to exhibit promising antiviral activity against SARS-CoV-2 in cell-based assays but its particular target action against specific non-structural and structural proteins of SARS-CoV-2 is unclear to date." | 1.72 | Ebselen suitably interacts with the potential SARS-CoV-2 targets: an ( Abdalla, M; Ali, N; Khalipha, ABR; Mondal, M; Sarkar, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 20 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Z | 1 |
| Du, X | 1 |
| Xu, Y | 1 |
| Deng, Y | 1 |
| Liu, M | 1 |
| Zhao, Y | 3 |
| Zhang, B | 1 |
| Li, X | 1 |
| Zhang, L | 2 |
| Peng, C | 1 |
| Duan, Y | 1 |
| Yu, J | 1 |
| Wang, L | 1 |
| Yang, K | 1 |
| Liu, F | 1 |
| Jiang, R | 1 |
| Yang, X | 2 |
| You, T | 1 |
| Liu, X | 4 |
| Bai, F | 1 |
| Liu, H | 1 |
| Guddat, LW | 1 |
| Xu, W | 1 |
| Xiao, G | 1 |
| Qin, C | 1 |
| Shi, Z | 1 |
| Jiang, H | 1 |
| Rao, Z | 1 |
| Yang, H | 1 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Cannalire, R | 1 |
| Cerchia, C | 1 |
| Beccari, AR | 1 |
| Di Leva, FS | 1 |
| Summa, V | 1 |
| Huff, S | 1 |
| Kummetha, IR | 1 |
| Tiwari, SK | 1 |
| Huante, MB | 1 |
| Clark, AE | 1 |
| Wang, S | 1 |
| Bray, W | 1 |
| Smith, D | 1 |
| Carlin, AF | 1 |
| Endsley, M | 1 |
| Rana, TM | 1 |
| Gao, S | 2 |
| Song, L | 2 |
| Claff, T | 2 |
| Woodson, M | 2 |
| Sylvester, K | 2 |
| Jing, L | 2 |
| Weiße, RH | 2 |
| Cheng, Y | 2 |
| Sträter, N | 2 |
| Schäkel, L | 2 |
| Gütschow, M | 2 |
| Ye, B | 2 |
| Yang, M | 2 |
| Zhang, T | 2 |
| Kang, D | 2 |
| Toth, K | 2 |
| Tavis, J | 2 |
| Tollefson, AE | 2 |
| Müller, CE | 2 |
| Zhan, P | 2 |
| Yu, W | 2 |
| Ye, H | 2 |
| Wu, N | 2 |
| Liao, Y | 2 |
| Chen, N | 2 |
| Li, Z | 2 |
| Wan, N | 2 |
| Hao, H | 2 |
| Yan, H | 2 |
| Xiao, Y | 2 |
| Lai, M | 2 |
| Sarkar, C | 1 |
| Abdalla, M | 1 |
| Mondal, M | 1 |
| Khalipha, ABR | 1 |
| Ali, N | 1 |
| Parise, A | 1 |
| Romeo, I | 1 |
| Russo, N | 1 |
| Marino, T | 1 |
| Qiao, Z | 1 |
| Wei, N | 1 |
| Jin, L | 1 |
| Zhang, H | 1 |
| Luo, J | 1 |
| Zhang, Y | 1 |
| Wang, K | 1 |
| Graf, D | 1 |
| Farn, N | 1 |
| Klopf, J | 1 |
| Hojjati, M | 1 |
| Schatzschneider, U | 1 |
| Zmudzinski, M | 1 |
| Rut, W | 1 |
| Olech, K | 1 |
| Granda, J | 1 |
| Giurg, M | 1 |
| Burda-Grabowska, M | 1 |
| Kaleta, R | 1 |
| Zgarbova, M | 1 |
| Kasprzyk, R | 1 |
| Sun, X | 1 |
| Lv, Z | 1 |
| Nayak, D | 1 |
| Kesik-Brodacka, M | 1 |
| Olsen, SK | 1 |
| Weber, J | 1 |
| Hilgenfeld, R | 1 |
| Jemielity, J | 1 |
| Drag, M | 1 |
| You, W | 1 |
| Chen, Y | 1 |
| Seale, LA | 1 |
| Torres, DJ | 1 |
| Berry, MJ | 1 |
| Pitts, MW | 1 |
| Sies, H | 1 |
| Parnham, MJ | 1 |
| Menéndez, CA | 1 |
| Byléhn, F | 1 |
| Perez-Lemus, GR | 1 |
| Alvarado, W | 1 |
| de Pablo, JJ | 1 |
| Zhang, J | 1 |
| Saad, R | 1 |
| Taylor, EW | 1 |
| Rayman, MP | 1 |
| Haritha, CV | 1 |
| Sharun, K | 1 |
| Jose, B | 1 |
| Servidio, C | 1 |
| Stellacci, F | 1 |
| Sun, LY | 1 |
| Chen, C | 1 |
| Su, J | 1 |
| Li, JQ | 1 |
| Jiang, Z | 1 |
| Gao, H | 1 |
| Chigan, JZ | 1 |
| Ding, HH | 1 |
| Zhai, L | 1 |
| Yang, KW | 1 |
| Nogara, PA | 1 |
| Omage, FB | 1 |
| Bolzan, GR | 1 |
| Delgado, CP | 1 |
| Aschner, M | 1 |
| Orian, L | 1 |
| Teixeira Rocha, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients[NCT04484025] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-10-12 | Enrolling by invitation | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients[NCT04483973] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-27 | Enrolling by invitation | ||
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
5 reviews available for ebselen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Str | 2022 |
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiviral Agents; Azoles; Betacoronavirus; Bi | 2020 |
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiviral Agents; Azoles; Betacoronavirus; Bi | 2020 |
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiviral Agents; Azoles; Betacoronavirus; Bi | 2020 |
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Antiviral Agents; Azoles; Betacoronavirus; Bi | 2020 |
Selenium and selenoproteins in viral infection with potential relevance to COVID-19.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Coronavirus 3C Proteases; COVID-19; COVID- | 2020 |
Therapeutic approaches against coronaviruses acute respiratory syndrome.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammator | 2021 |
15 other studies available for ebselen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
Topics: Animals; Antiviral Agents; Benzothiazoles; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19; | 2022 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; | 2022 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; | 2022 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; | 2022 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; | 2022 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Pa | 2022 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Pa | 2022 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Pa | 2022 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Pa | 2022 |
Ebselen suitably interacts with the potential SARS-CoV-2 targets: an
Topics: Antiviral Agents; Azoles; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; M | 2022 |
The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
Topics: Antiviral Agents; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug | 2021 |
The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Topics: Antiviral Agents; Binding Sites; Catalytic Domain; Cell Line; Cell Survival; Chromatography, High Pr | 2021 |
Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease.
Topics: Coumarins; COVID-19; Cysteine Endopeptidases; Humans; Metallocenes; Molecular Docking Simulation; Pr | 2023 |
Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
Topics: Antiviral Agents; COVID-19; Cysteine Endopeptidases; Humans; Methyltransferases; Molecular Docking S | 2023 |
Exploring the inhibition mechanism of SARS-CoV-2 main protease by ebselen: A molecular docking, molecular dynamics simulation and DFT approach.
Topics: COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2 | 2023 |
A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.
Topics: Azoles; Betacoronavirus; Coronavirus Infections; COVID-19; Glutathione Peroxidase; Humans; Isoindole | 2020 |
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Topics: Antiviral Agents; Azoles; Betacoronavirus; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases | 2020 |
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Topics: Antiviral Agents; Azoles; Betacoronavirus; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases | 2020 |
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Topics: Antiviral Agents; Azoles; Betacoronavirus; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases | 2020 |
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Topics: Antiviral Agents; Azoles; Betacoronavirus; Binding Sites; Catalytic Domain; Coronavirus 3C Proteases | 2020 |
Ebselen, a new candidate therapeutic against SARS-CoV-2.
Topics: Azoles; COVID-19; Humans; Isoindoles; Laboratories; Organoselenium Compounds; Polymerase Chain React | 2020 |
Ebselen, a new candidate therapeutic against SARS-CoV-2.
Topics: Azoles; COVID-19; Humans; Isoindoles; Laboratories; Organoselenium Compounds; Polymerase Chain React | 2020 |
Ebselen, a new candidate therapeutic against SARS-CoV-2.
Topics: Azoles; COVID-19; Humans; Isoindoles; Laboratories; Organoselenium Compounds; Polymerase Chain React | 2020 |
Ebselen, a new candidate therapeutic against SARS-CoV-2.
Topics: Azoles; COVID-19; Humans; Isoindoles; Laboratories; Organoselenium Compounds; Polymerase Chain React | 2020 |
Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
Topics: Antiviral Agents; Azoles; Binding Sites; Catalytic Domain; COVID-19; COVID-19 Drug Treatment; Fluore | 2021 |
In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Topics: Antiviral Agents; Azoles; Catalytic Domain; Coronavirus Papain-Like Proteases; COVID-19; COVID-19 Dr | 2021 |